2026 ICD-10-CM Diagnosis Code T80.82XSComplication of immune effector cellular therapy, sequela
T80.82XS is a billable ICD-10-CM diagnosis code for complication of immune effector cellular therapy, sequela. The 7th character S marks it as a sequela code, which reports a problem that remains after the original condition has resolved. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 922 through 923. The code is exempt from POA reporting. Coders also document this condition as acute intoxication. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Complication, sequela.
Code Identity
Code Classification
Present on Admission (POA)Billing
T80.82XS is exempt from POA reporting on inpatient claims to general acute care hospitals. Review other POA exempt codes.
Approximate SynonymsGuidance
Alternate terms and clinical phrases that map to this code.
- Acute intoxication
- Cytokine release syndrome
- Cytokine release syndrome due to chimeric antigen receptor T-cell immunotherapy
- Immune effector cell-associated neurotoxicity syndrome
- Immune system complication of procedure
Coding GuidelinesGuidance
The appropriate 7th character is to be added to each code from block Complications following infusion, transfusion and therapeutic injection (T80). Use the following options for the applicable episode of care:
- A - initial encounter
- D - subsequent encounter
- S - sequela
Source: ICD-10-CM Official Guidelines for Coding and Reporting, FY 2026, published by CMS and the National Center for Health Statistics.
Clinical ClassificationClinical
AHRQ’s CCSR groups this code into broader clinical categories.
Clinical InformationClinical
Cytokine Release Syndrome
a severe immune reaction characterized by excessive release of cytokines. symptoms include dyspnea; fever; headache; hypotension; nausea; rash; tachycardia; hypoxia; hyperferritinemia, and multiple organ failure. it is associated with viral infections, sepsis; autoimmune diseases and a variety of factors used in immunotherapy.
Code History & ChangesHistory
Replacement T80.82XS replaces the following previously assigned code(s):
- T80.89XS - Oth comp fol infusion, tranfs and theraputc inject, sequela
Questions About T80.82XSOverview
Is T80.82XS (Complication of immune effector cellular therapy) a billable code?
Yes. This is a billable ICD-10-CM code, specific enough to report complication of immune effector cellular therapy, sequela on HIPAA-covered claims from October 1, 2025 through September 30, 2026.
What does the 7th character S in T80.82XS mean?
The final character S makes this a sequela code: it reports a lingering problem that remains after the complication of immune effector cellular therapy itself has resolved, not the original event.
What MS-DRG does T80.82XS group to?
When complication of immune effector cellular therapy, sequela is the principal diagnosis on an inpatient stay, it groups to MS-DRG 922, 923, with relative weights from 1.0177 to 1.7494 depending on complications. Higher weights mean higher Medicare reimbursement.
Is T80.82XS exempt from POA reporting?
Yes. CMS lists this code among those exempt from present on admission reporting, so hospitals do not assign a POA indicator for complication of immune effector cellular therapy, sequela on inpatient claims.
Footnotes
[1] Not chronic - A diagnosis code that does not fit the criteria for chronic condition (duration, ongoing medical treatment, and limitations) is considered not chronic. Some codes designated as not chronic are acute conditions. Other diagnosis codes that indicate a possible chronic condition, but for which the duration of the illness is not specified in the code description (i.e., we do not know the condition has lasted 12 months or longer) also are considered not chronic.
